Summary

The CAR T cell therapy market is witnessing remarkable growth due to increasing adoption of personalized cancer treatment approaches and advancements in immunotherapy technologies. CAR T cell therapy has emerged as a revolutionary treatment option for hematological malignancies, offering improved survival outcomes for patients with relapsed or refractory cancers. Growing investments in oncology research and rising approvals of innovative cell-based therapies are significantly contributing to market expansion. The market is expected to reach US$ 7.2 Bn in 2026 and US$ 10.7 Bn by 2033, growing at a CAGR of 5.80% during the forecast period.

Market Insights:

The industry is evolving rapidly with continuous advancements in genetic engineering, cell manufacturing technologies, and next-generation CAR T platforms. Pharmaceutical and biotechnology companies are increasingly focusing on expanding CAR T applications beyond blood cancers into solid tumors. Rising clinical trial activities and ongoing research aimed at improving therapy efficacy and reducing adverse effects are strengthening market development. In addition, improvements in cell processing technologies and growing collaborations between healthcare institutions and biopharmaceutical companies are enhancing commercialization opportunities for CAR T therapies worldwide.

Drivers:

Major drivers of the CAR T cell therapy market include the increasing prevalence of hematological cancers, growing demand for targeted therapies, and rising success rates of immunotherapy treatments. The expanding geriatric population and growing incidence of leukemia, lymphoma, and multiple myeloma are creating strong demand for advanced cancer therapies. Favorable regulatory support for breakthrough therapies and increasing investment in cancer research are further accelerating market growth. Additionally, advancements in biotechnology and gene editing technologies are improving treatment outcomes and supporting broader adoption of CAR T cell therapies.

Business Opportunity:

The market presents substantial opportunities for companies investing in next-generation CAR T therapies, allogeneic cell therapies, and automated cell manufacturing technologies. Emerging economies are creating lucrative growth prospects due to improving oncology treatment infrastructure and increasing healthcare expenditure. Strategic partnerships between biotechnology firms, research organizations, and hospitals are expected to drive innovation and accelerate product development. Furthermore, expanding applications of CAR T therapies for solid tumors and autoimmune diseases are likely to open new revenue streams for market participants in the coming years.

Region Analysis:

North America dominates the CAR T cell therapy market owing to strong biotechnology research capabilities, high healthcare spending, and early adoption of advanced cancer therapies. The presence of major pharmaceutical companies and favorable reimbursement policies further support market growth in the region. Europe holds a significant share driven by increasing investment in oncology research and growing approvals for innovative immunotherapies. Asia Pacific is expected to witness the fastest growth due to rising cancer prevalence, expanding healthcare infrastructure, and increasing investments in biotechnology sectors in countries such as China, Japan, and India. Latin America and the Middle East & Africa are gradually emerging as potential markets with improving access to advanced cancer treatments and growing awareness regarding immunotherapy solutions.

Key Players:

• Bristol-Myers Squibb Company (US)

• Johnson & Johnson (US)

• Gilead Sciences, Inc. (US)

• Novartis AG (Switzerland)

• JW (Cayman) Therapeutics Co. Ltd (China)

• ImmunoACT (India)

• CARsgen Therapeutics Holdings Limited (China)

• IASO biotherapeutics (China)

• Autolus Therapeutics (UK)

• Cartesian Therapeutics, Inc. (US)

Segmentation:

By Product

• Yescarta

• Kymriah

• JCAR017

• Bb2121

By Indication

• Relapsed Large B-Cell Lymphoma

• Acute Lymphoblastic Leukemia (ALL)

• Multiple Myeloma

By End User

• Hospitals

• Cancer Treatment Centers

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• The Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Car T Cell Therapy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2026
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Five Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2025-2033
2.9.2. Price Impact Factors
3. Global Car T Cell Therapy Market Outlook, 2020 - 2033
3.1. Global Car T Cell Therapy Market Outlook, by Product, Value (US$ Bn), 2020-2033
3.1.1. Yescarta
3.1.2. Kymriah
3.1.3. JCAR017
3.1.4. Bb2121
3.2. Global Car T Cell Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
3.2.1. Relapsed Large B-Cell Lymphoma
3.2.2. Acute Lymphoblastic Leukemia (ALL)
3.2.3. Multiple Myeloma
3.3. Global Car T Cell Therapy Market Outlook, by End User, Value (US$ Bn), 2020-2033
3.3.1. Hospitals
3.3.2. Cancer Treatment Centers
3.4. Global Car T Cell Therapy Market Outlook, by Region, Value (US$ Bn), 2020-2033
3.4.1. North America
3.4.2. Europe
3.4.3. Asia Pacific
3.4.4. Latin America
3.4.5. Middle East & Africa
4. North America Car T Cell Therapy Market Outlook, 2020 - 2033
4.1. North America Car T Cell Therapy Market Outlook, by Product, Value (US$ Bn), 2020-2033
4.1.1. Yescarta
4.1.2. Kymriah
4.1.3. JCAR017
4.1.4. Bb2121
4.2. North America Car T Cell Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
4.2.1. Relapsed Large B-Cell Lymphoma
4.2.2. Acute Lymphoblastic Leukemia (ALL)
4.2.3. Multiple Myeloma
4.3. North America Car T Cell Therapy Market Outlook, by End User, Value (US$ Bn), 2020-2033
4.3.1. Hospitals
4.3.2. Cancer Treatment Centers
4.4. North America Car T Cell Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
4.4.1. U.S. Car T Cell Therapy Market Outlook, by Product, 2020-2033
4.4.2. U.S. Car T Cell Therapy Market Outlook, by Indication, 2020-2033
4.4.3. U.S. Car T Cell Therapy Market Outlook, by End User, 2020-2033
4.4.4. Canada Car T Cell Therapy Market Outlook, by Product, 2020-2033
4.4.5. Canada Car T Cell Therapy Market Outlook, by Indication, 2020-2033
4.4.6. Canada Car T Cell Therapy Market Outlook, by End User, 2020-2033
4.5. BPS Analysis/Market Attractiveness Analysis
5. Europe Car T Cell Therapy Market Outlook, 2020 - 2033
5.1. Europe Car T Cell Therapy Market Outlook, by Product, Value (US$ Bn), 2020-2033
5.1.1. Yescarta
5.1.2. Kymriah
5.1.3. JCAR017
5.1.4. Bb2121
5.2. Europe Car T Cell Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
5.2.1. Relapsed Large B-Cell Lymphoma
5.2.2. Acute Lymphoblastic Leukemia (ALL)
5.2.3. Multiple Myeloma
5.3. Europe Car T Cell Therapy Market Outlook, by End User, Value (US$ Bn), 2020-2033
5.3.1. Hospitals
5.3.2. Cancer Treatment Centers
5.4. Europe Car T Cell Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
5.4.1. Germany Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.2. Germany Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.3. Germany Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.4.4. Italy Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.5. Italy Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.6. Italy Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.4.7. France Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.8. France Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.9. France Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.4.10. U.K. Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.11. U.K. Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.12. U.K. Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.4.13. Spain Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.14. Spain Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.15. Spain Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.4.16. Russia Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.17. Russia Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.18. Russia Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.4.19. Rest of Europe Car T Cell Therapy Market Outlook, by Product, 2020-2033
5.4.20. Rest of Europe Car T Cell Therapy Market Outlook, by Indication, 2020-2033
5.4.21. Rest of Europe Car T Cell Therapy Market Outlook, by End User, 2020-2033
5.5. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Car T Cell Therapy Market Outlook, 2020 - 2033
6.1. Asia Pacific Car T Cell Therapy Market Outlook, by Product, Value (US$ Bn), 2020-2033
6.1.1. Yescarta
6.1.2. Kymriah
6.1.3. JCAR017
6.1.4. Bb2121
6.2. Asia Pacific Car T Cell Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
6.2.1. Relapsed Large B-Cell Lymphoma
6.2.2. Acute Lymphoblastic Leukemia (ALL)
6.2.3. Multiple Myeloma
6.3. Asia Pacific Car T Cell Therapy Market Outlook, by End User, Value (US$ Bn), 2020-2033
6.3.1. Hospitals
6.3.2. Cancer Treatment Centers
6.4. Asia Pacific Car T Cell Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
6.4.1. China Car T Cell Therapy Market Outlook, by Product, 2020-2033
6.4.2. China Car T Cell Therapy Market Outlook, by Indication, 2020-2033
6.4.3. China Car T Cell Therapy Market Outlook, by End User, 2020-2033
6.4.4. Japan Car T Cell Therapy Market Outlook, by Product, 2020-2033
6.4.5. Japan Car T Cell Therapy Market Outlook, by Indication, 2020-2033
6.4.6. Japan Car T Cell Therapy Market Outlook, by End User, 2020-2033
6.4.7. South Korea Car T Cell Therapy Market Outlook, by Product, 2020-2033
6.4.8. South Korea Car T Cell Therapy Market Outlook, by Indication, 2020-2033
6.4.9. South Korea Car T Cell Therapy Market Outlook, by End User, 2020-2033
6.4.10. India Car T Cell Therapy Market Outlook, by Product, 2020-2033
6.4.11. India Car T Cell Therapy Market Outlook, by Indication, 2020-2033
6.4.12. India Car T Cell Therapy Market Outlook, by End User, 2020-2033
6.4.13. Southeast Asia Car T Cell Therapy Market Outlook, by Product, 2020-2033
6.4.14. Southeast Asia Car T Cell Therapy Market Outlook, by Indication, 2020-2033
6.4.15. Southeast Asia Car T Cell Therapy Market Outlook, by End User, 2020-2033
6.4.16. Rest of SAO Car T Cell Therapy Market Outlook, by Product, 2020-2033
6.4.17. Rest of SAO Car T Cell Therapy Market Outlook, by Indication, 2020-2033
6.4.18. Rest of SAO Car T Cell Therapy Market Outlook, by End User, 2020-2033
6.5. BPS Analysis/Market Attractiveness Analysis
7. Latin America Car T Cell Therapy Market Outlook, 2020 - 2033
7.1. Latin America Car T Cell Therapy Market Outlook, by Product, Value (US$ Bn), 2020-2033
7.1.1. Yescarta
7.1.2. Kymriah
7.1.3. JCAR017
7.1.4. Bb2121
7.2. Latin America Car T Cell Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
7.2.1. Relapsed Large B-Cell Lymphoma
7.2.2. Acute Lymphoblastic Leukemia (ALL)
7.2.3. Multiple Myeloma
7.3. Latin America Car T Cell Therapy Market Outlook, by End User, Value (US$ Bn), 2020-2033
7.3.1. Hospitals
7.3.2. Cancer Treatment Centers
7.4. Latin America Car T Cell Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
7.4.1. Brazil Car T Cell Therapy Market Outlook, by Product, 2020-2033
7.4.2. Brazil Car T Cell Therapy Market Outlook, by Indication, 2020-2033
7.4.3. Brazil Car T Cell Therapy Market Outlook, by End User, 2020-2033
7.4.4. Mexico Car T Cell Therapy Market Outlook, by Product, 2020-2033
7.4.5. Mexico Car T Cell Therapy Market Outlook, by Indication, 2020-2033
7.4.6. Mexico Car T Cell Therapy Market Outlook, by End User, 2020-2033
7.4.7. Argentina Car T Cell Therapy Market Outlook, by Product, 2020-2033
7.4.8. Argentina Car T Cell Therapy Market Outlook, by Indication, 2020-2033
7.4.9. Argentina Car T Cell Therapy Market Outlook, by End User, 2020-2033
7.4.10. Rest of LATAM Car T Cell Therapy Market Outlook, by Product, 2020-2033
7.4.11. Rest of LATAM Car T Cell Therapy Market Outlook, by Indication, 2020-2033
7.4.12. Rest of LATAM Car T Cell Therapy Market Outlook, by End User, 2020-2033
7.5. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Car T Cell Therapy Market Outlook, 2020 - 2033
8.1. Middle East & Africa Car T Cell Therapy Market Outlook, by Product, Value (US$ Bn), 2020-2033
8.1.1. Yescarta
8.1.2. Kymriah
8.1.3. JCAR017
8.1.4. Bb2121
8.2. Middle East & Africa Car T Cell Therapy Market Outlook, by Indication, Value (US$ Bn), 2020-2033
8.2.1. Relapsed Large B-Cell Lymphoma
8.2.2. Acute Lymphoblastic Leukemia (ALL)
8.2.3. Multiple Myeloma
8.3. Middle East & Africa Car T Cell Therapy Market Outlook, by End User, Value (US$ Bn), 2020-2033
8.3.1. Hospitals
8.3.2. Cancer Treatment Centers
8.4. Middle East & Africa Car T Cell Therapy Market Outlook, by Country, Value (US$ Bn), 2020-2033
8.4.1. GCC Car T Cell Therapy Market Outlook, by Product, 2020-2033
8.4.2. GCC Car T Cell Therapy Market Outlook, by Indication, 2020-2033
8.4.3. GCC Car T Cell Therapy Market Outlook, by End User, 2020-2033
8.4.4. South Africa Car T Cell Therapy Market Outlook, by Product, 2020-2033
8.4.5. South Africa Car T Cell Therapy Market Outlook, by Indication, 2020-2033
8.4.6. South Africa Car T Cell Therapy Market Outlook, by End User, 2020-2033
8.4.7. Egypt Car T Cell Therapy Market Outlook, by Product, 2020-2033
8.4.8. Egypt Car T Cell Therapy Market Outlook, by Indication, 2020-2033
8.4.9. Egypt Car T Cell Therapy Market Outlook, by End User, 2020-2033
8.4.10. Nigeria Car T Cell Therapy Market Outlook, by Product, 2020-2033
8.4.11. Nigeria Car T Cell Therapy Market Outlook, by Indication, 2020-2033
8.4.12. Nigeria Car T Cell Therapy Market Outlook, by End User, 2020-2033
8.4.13. Rest of Middle East Car T Cell Therapy Market Outlook, by Product, 2020-2033
8.4.14. Rest of Middle East Car T Cell Therapy Market Outlook, by Indication, 2020-2033
8.4.15. Rest of Middle East Car T Cell Therapy Market Outlook, by End User, 2020-2033
8.5. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Bristol-Myers Squibb Company (US)
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Johnson & Johnson (US)
9.4.3. Gilead Sciences, Inc. (US)
9.4.4. Novartis AG (Switzerland)
9.4.5. JW (Cayman) Therapeutics Co. Ltd (China)
9.4.6. ImmunoACT (India)
9.4.7. CARsgen Therapeutics Holdings Limited (China)
9.4.8. IASO biotherapeutics (China)
9.4.9. Autolus Therapeutics (UK)
9.4.10. Cartesian Therapeutics, Inc. (US)
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations